

0590 0360
PATENT

Case Docket No. MVIEWD.1A2DV1

Date: September 17, 2001


#10
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Williams, et al.
Appl. No. : 09/839,946
Filed : April 19, 2001
For : PEG-URATE OXIDASE
CONJUGATES AND USE
THEREOF
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

September 17, 2001

(Date)


-Sam K. Tahmassebi, Reg. No. 45,151


TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231
ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 listing forty-three (43) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Williams, et al.) Group Art Unit Unknown
App. No. : 09/839,946)
Filed : April 19, 2001)
For : PEG-URATE OXIDASE)
CONJUGATES AND USE)
THEREOF)
Examiner : Unknown)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing forty-three (43) references. These references were of record in U.S. Patent Application Number 09/370,084, filed August 6, 1999, from which the above identified application claims priority under 35 U.S.C. §120. Accordingly, pursuant to 37 C.F.R. §1.98(d), these references are not enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Sept. 17, 2001

By: [Signature]

Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(619) 235-8550

 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. MVIEWD.1A2DV1	APPLICATION NO. 09/839,946
	APPLICANT Williams, et al.	
	FILING DATE April 19, 2001	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	3,616,231	10/26/71	Bergmeyer et al.			
	2	4,460,683	07/17/84	Gloger et al.			
	3	4,766,106	08/23/88	Katre et al.			
	4	4,847,325	07/11/89	Shadle et al.			
	5	5,286,637	02/15/94	Veronese et al.			
	6	5,382,518	01/17/95	Caput et al.			
	7	5,541,098	07/30/96	Caput et al.			
	8	5,612,460	03/18/97	Zalipsky			
	9	5,653,974	08/05/97	Hung et al.			
	10	5,643,575	07/01/97	Martinez et al.			
	11	5,880,255	03/09/99	Delgado et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	12	DD 279 486 A1	06/06/90	East Germany				X
	13	DD 279 486 A1	06/06/90	East Germany-Abstract			X	
	14	09154581	06/17/97	Japan				X
	15	09154581	06/17/97	Japan-Abstract			X	
	16	WO 94/19007	09/01/94	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	17	Abuchowski et al., (1976), Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase, <u>The Journal of Biochemical Chemistry</u> 252:3582-3586
	18	Burnham, Nora, (1994), Polymers for Delivering Peptides and Proteins, <u>Am. J. Hosp. Pharm.</u> 51:210-218
	19	Chua et al., (1988), Use of Polyethylene Glycol-Modified Uricase (PEG-Uricase) to Treat Hyperuricemia in a Patient with Non-Hodgkin Lymphoma, <u>Annals of Internal Medicine</u> 109:114-117.
	20	Davis et al., (1981), Hypouricaemic Effect of Polyethyleneglycol Modified Urate Oxide, <u>The Lancet</u> pgs. 281-283.
	21	Davis et al., (1978), Enzyme-Polyethylene Glycol Adducts: Modified Enzymes with Unique Properties, <u>Enzyme Engineering</u> 4:169-173.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FORM PTOL-49 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. MVIEWD.1A2DV1	APPLICATION NO. 09/839,946
	APPLICANT Williams, et al.	
	FILING DATE April 19, 2001	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	22	Donadio et al., (1981), Manifestation De Type Anaphylactique Apres Injection Intra-Veineuse D'urate-Oxydase Chez Un Enfant Asthmatique Atteint De Leucemie Aigue, <u>La Nouvelle Presse Medicale</u> 28:711-712.
	23	Fam (1990), Strategies and Controversies in the Treatment of Gout and Hyperuricaemia, <u>Clinical Rheumatology International Practice and Research</u> 4:177-192.
	24	Hande et al., (1984), Severe Allopurinol Toxicity, <u>The American Journal of Medicine</u> 76:47-56.
	25	Hedlund et al., (1991), Magnetic Resonance Microscopy of Toxic Renal Injury Induced by Bromoethylamine in Rats, <u>Fundamental and Applied Toxicology</u> 16:787-797.
	26	Kahn, et al., (1997), Kinetic Mechanism and Cofactor Content of Soybean Root Nodule Urate Oxidase, <u>American Chemical Society</u> 36:4731-4738.
	27	Kunitani et al., (1991), On-Line Characterization of Polyethylene Glycol-Modified Proteins, <u>Journal of Chromatography</u> 588:125-137.
	28	Leach et al., (1998), Efficacy of Urate Oxidase (Uricozyme) in Tumor Lysis Induced Urate Nephropathy, <u>Blackwell Science Limited</u> 20:169-172.
	29	Legoux et al., (1991), Cloning and Expression in Escherichia coli of the Gene Encoding Aspergillus flavus Urate Oxidase <u>The Journal of Biological Chemistry</u> 267:8565-8570.
	30	Mahmound et al., (1998), Advances in the Management of Malignancy-Associated Hyperuricaemia, <u>British Journal of Cancer</u> 77:18-20.
	31	Miura et al., (1994), Urate Oxidase is Imported into Peroxisomes Recognizing the C-terminal SKL Motif of Proteins, <u>Eur. J. Biochem</u> 223:141-146.
	32	Nishimura et al., (1981), Improved Modification of Yeast Uricase with Polyethylene Glycol, Accompanied with Nonimmunoreactivity towards Anti-Uricase Serum and High Enzymic Activity, <u>Enzyme</u> 26:49-53.
	33	Nucci et al., (1991), The Therapeutic Value of Poly(Ethylene Glycol)-Modified Proteins, <u>Advanced Drug Delivery Reviews</u> 6:133-151.
	34	Pui et al., (1997), Urate Oxidase in Prevention and Treatment of Hyperuricemia Associated with Lymphoid Malignancies, <u>Leukemia</u> 11:1813-1816.
	35	Shearwater Polymers, Inc. (1997-1998), Functionalized Biocompatible Polymers for Research and Pharmaceuticals, <u>Shearwater Polymers, Inc. Catalog</u> 27, 47, 48.
	36	Saifer, et al., (1994), Plasma Clearance and Immunologic Properties of Long-Acting Superoxide Dismutase Prepared Using 35,000 to 120,000 Dalton Poly-Ethylene Glycol, <u>Advances in Experimental Medicine and Biology</u> 366:377-387.
	37	Sartore et al., (1991), Enzyme Modification by MPEG with an Amino Acid or Peptide as Spacer Arms, <u>Applied Biochemistry and Biotechnology</u> 27: 45-54.
	38	Venkateshan et al., (1990), Acute Hyperuricemic Nephropathy and Renal Failure after Transplantation, <u>Nephron</u> 56:317-321.
	39	Veronese et al., (1985), Surface Modification of Proteins, <u>Applied Biochemistry and Biotechnology</u> 11:141-152.
	40	Veronese et al., (1997), New Synthetic Polymers for Enzyme and Liposome Modification in <u>Poly(ethylene Glycol) Chemistry and Biological Applications</u> , Chapter 13:182-192.
	41	Wu et al., (1989), Urate Oxidase: Primary Structure and Evolutionary Implications <u>Proc. Natl. Acad. Sci. USA</u> 86:9412-9416.
	42	Wu et al, (1984), Hyperuricemia and Urate Nephropathy in Urate Oxidase-Deficient Mice <u>Proc. Natl. Acad. Sci. USA</u> 91:742-746.
	43	Yasuda et al., (1990), Biochemical and Biopharmaceutical Properties of Macromolecular Conjugates of Uricase with Dextran and Polyethylene Glycol. <u>Chem. Pharm. Bull.</u> 38:2053-2056.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	